ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts

Cancer Research

Volumn 56, Issue 14, 1996, Pages 3287-3292

  Blakey, David C ^a   Burke, Philip J ^b   Davies, David H ^a   Dowell, Robert I ^a   East, Simon J ^a   Eckersley, Kay P ^a   Fitton, John E ^a   McDaid, John ^a   Melton, Roger G ^c   Niculescu Duvaz, Ion A ^d   Pinder, Philip E ^a   Sharma, Surinder K ^b   Wright, Andrew F ^a   Springer, Caroline J ^d  

^a ASTRAZENECA   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; CARBOXYPEPTIDASE G2; CARCINOEMBRYONIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER REGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; COLORECTAL NEOPLASMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; HUMANS; IMMUNOTOXINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS;

EID: 8944233863     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bagshawe, K. D. Antibody-directed enzyme prodrug therapy (ADEPT) Adv. Pharmacol., 24: 99-121, 1993.
2. Knox, R. J., and Connors, T. A. Antibody-directed enzyme prodrug therapy. Clin Immunother., 3: 136-153, 1995
3. Niculescu-Duvaz, I., and Springer, C. J. Antibody-directed enzyme prodrug therapy (ADEPT), a targeting strategy in cancer chemotherapy Current Medicinal Chemistry, 2: 687-706, 1995.
4. Blakey, D. C , Burke, P. J., Davies, D. H., Dowell, R. I., Melton, R. G., Springer, C. J , and Wright, A. F. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease. Biochem. Soc. Trans., 23: 1047-1050, 1995
5. Woodruff, M F. A Cellular heterogeneity in tumours Br. J Cancer, 47: 589-594, 1983.
6. Jain, R. K. Delivery of novel therapeutic agents to tumors physiological barriers and strategies. J. Natl. Cancer Inst., 81: 570-576, 1989
7. Vrudhula, V. M., Svensson, H. P., Kennedy, K. A., Senter, P. D., and Wallace, P. M. Antitumour activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconjugate Chem , 4: 334-340, 1993.
8. Meyer, D L., Jungheim, L N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G , Briggs, S. L , and Starling, J. J. Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res., 53: 3956-3963, 1993.
9. Bosslet, K., Czech, J , and Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res., 54: 2151-2159, 1994
10. Senter, P. D., Saulnier, M. G., Schreiber, G J., Hirschberg, D L., Brown, J. P., Hellstrom, I., and Hellstrom, K. E Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci. USA, 85 4842-4846, 1988
11. Sherwood, R. F., Melton, R. G., Alwan, S M., and Hughes, P Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16: use of a novel triazine-dye affinity method Eur. J. Biochem , 148: 447-453, 1985.
12. Bagshawe, K. D., Springer, C. J , Searle, F., Antoniw, P., Sharma, S K., Melton, R. G , and Sherwood, R. F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 58 700-703, 1988
13. Springer, C. J., Bagshawe, K. D , Sharma, S K , Searle, F., Boden, J. A., Antoniw, P., Burke, P. J , Rogers, G. T., Sherwood, R. F , and Melton, R G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds Eur. J Cancer, 27: 1361-1366, 1991.
14. Blakey, D C., Valcaccia, B. E., East, S , Wright, A. F., Boyle, F. T , Springer, C J., Burke, P. J , Melton, R. G , and Bagshawe, K. D. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys , 22: 1-8, 1993.
15. Sharma, S K , Bagshawe, K. D , Springer, C. J , Burke, P. J , Rogers, G. T , Boden, J A., Antoniw, P , Melton, R. G , and Sherwood, R F. Antibody-directed enzyme prodrug therapy (ADEPT): a three-phase system. Dis. Markers, 9: 225-231, 1991.
16. Sharma, S. K., Boden, J A., Springer, C. J., Burke, P. J., and Bagshawe, K D. Antibody-directed enzyme prodrug therapy (ADEPT): a three-phase study in ovarian tumour xenografts Cell Biophys., 24: 219-228, 1994.
17. Bagshawe, K. D., Sharma, S. K., Springer, C J , and Antoniw, P. Antibody-directed enzyme prodrug therapy a pilot-scale clinical trial Tumor Targeting, 1: 17-29, 1995.
18. Sikorska, H., Shuster, J , and Gold, P Clinical applications of carcinoembryonic antigen Cancer Detect Prev., 12: 321-355, 1988
19. Springer, C J., Antoniw, P , Bagshawe, K. D , and Wilman, D E V. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Design, 6: 467-479, 1991.
20. Antoniw, P , Springer, C J , Bagshawe, K. D., Searle, F., Melton, R G., Rogers, G T., Burke, P. J., and Sherwood, R F Disposition of the prodrug 4-(bis(2-chloroethyl)amino)benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer, 62: 909-914, 1990.
21. Blakey, D C., Davies, D H , Dowell, R. I , East, S. J , Burke, P J , Sharma, S K., Springer, C. J , Mauger, A. B., and Melton, R. G. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br. J. Cancer, 72: 1083-1088, 1995.
22. Springer, C. J., Dowell, R , Burke, P. J , Hadley, E , Davies, D. H., Blakey, D. C., Melton, R. G., and Niculescu-Duvaz, I. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J. Med. Chem., 38: 5051-5065, 1995.
23. Minton, N. P., Atkinson, T , and Sherwood, R. F. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia colt and Pseudomonas putida. J. Bacteriol., 156: 1222-1227, 1983.
24. Harwood, P. J., Britton, D. W , Southall, P. J., Boxer, G M., Rawlins, G , and Rogers G. T. Mapping epitope characteristics on carcinoembryonic antigen. Br. J Cancer, 54 75-82, 1986
25. Melton, R G., Boyle, J M. B., Rogers, G T., Burke, P., Bagshawe, K. D., and Sherwood, R. F. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J. Immunol. Methods, 158: 49-56, 1993.
26. Skehan, P., Storeng, R , Scudiero, D. Monks, A , McMahon, J., Vistica, D , Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colonmetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990
27. Armitage, P., and Berry, G. Statistical Methods in Medical Research. Oxford, United Kingdom: Blackwell Scientific Publications, Ltd., 1987.
28. Yuan, F., Baxter, L. T., and Jain, R. K. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies Cancer Res., 51: 3119-3130, 1991.
29. Denny, W A , and Wilson, W. R. Bioreducible mustards, a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev , 12: 135-151, 1993.
30. Frei, E., III., Teicher, B A., Holden, S. A., Cathcart, K N. S , and Wang, Y. Preclinical studies and clinical correlation of the effect of alkylating dose Cancer Res., 48 6417-6423, 1988
31. Shimomatsuya, T., Tanigawa, N., and Muraoka, R. Proliferation activity of human tumours assessment using bromodeoxyuridine and flow cytometry. Jpn J. Carcer Res., 82: 357-362, 1991
32. 2-CPG2) conjugate in ADEPT. Antibody Immunoconj. Radiopharm 8: 62, 1995.
33. Sharma, S K., Bagshawe, K. D., Burke, P. J., Boden, R. W., and Rogers, G. T. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model Br. J Cancer, 61: 659-662, 1990.
34. Petrelli, N , Douglass, H. O., Herrera, L , Russell, D , Stablein, D M , Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., Muggia, F. M., Megibow, A , Greenwald, E S , Bukowski, R. M., Harris, J., Levin, B., Gaynor, E , Loutfi, A , Kasler, M. H., Barkin, J S., Benedetto, P., Woolley, P. V , Nauta, R., Weaver, D W , and Leichman, L. P. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma, a prospective randomized phase-III trial. J. Clin. Oncol., 7: 1419-1426, 1989.
35. Boxer, G M., Begent, R. H. J., Kelly, A. M. B., Southall, P J., Blair, S B , Theodorou, N. A., Dawson, P. M., and Ledermann, J. A. Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma, implications for radioimmunotherapy. Br. J. Cancer, 65: 825-831, 1992.